Loading...
Loading...
Clinical trial failures, poor sales and crushing debt pummeled shares of Vermillion, Oxigene and Angiotech in 2010.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
